Ovarian Cancer Vaccine for Patients in Remission

Status:	Archived
Conditions:	Ovarian Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	Any
Updated:	7/1/2011
Start Date:	February 2010
End Date:	February 2013

A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission

The purpose of this study is to determine the safety and efficacy of an investigational
vaccine in ovarian cancer patients in remission and to determine its ability to prevent
cancer from returning.

STUDY OBJECTIVES:

The purpose of this trial is to determine the safety and efficacy of CVac compared with
Standard of Care in ovarian cancer patients who are in remission after first or second-line
therapy.

Primary Objectives:

- To confirm the safety of administering CVac in this population.

- To determine the effects of CVac on progression-free survival (PFS).

Secondary Objectives:

- To determine overall survival (OS) for recurrent ovarian cancer patients who receive
CVac after achieving remission in the first or second-line setting.

- Evaluation of host immunologic response to CVac administration.

We found this trial at

sites

Stanford University Dept. of Medicine-Oncology

Stanford, California 94305

from

Stanford, CA